Over the past year, we have seen incredible progress in Alzheimer’s drugs, diagnostics, and prevention methods. But this is still only the beginning. Dr. Mark Mintun, Group Vice President of Neuroscience Research and Development at Eli Lilly and Company, will discuss his role leading the phase 3 study of Lilly’s Alzheimer’s drug donanemab, as well as directions for the future of research. Drugs like Lilly’s are expanding our arsenal and moving us closer to the holy grail for treating Alzheimer’s: combination therapies and precision medicine.
“Tomorrow’s Breakthroughs Today” features world-class scientists discussing the path toward new, cutting-edge treatments for Alzheimer’s disease. Now in its fourth season and second at The Four Arts, this lecture series, founded in partnership with Heidi and Tom McWilliams, invites three top investigators to share the latest breaking updates on their research with moderator Dr. Howard Fillit, Co-Founder and Chief Science Officer of the Alzheimer’s Drug Discovery Foundation (ADDF). Founded in 1998 by Leonard A. and Ronald S. Lauder, the ADDF is dedicated to rapidly accelerating the development of novel therapeutics and biomarkers to prevent, treat, and cure Alzheimer’s disease and related dementias.
Presented by the Alzheimer’s Drug Discovery Foundation in partnership with Heidi and Tom McWilliams
